Drugs / GSK2302025A
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01149343 | Jul 2010 → Feb 2014 | melanoma | GlaxoSmithKline | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GSK2302025A | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01149343 ↗ |
| Modality | Vaccine | “Male or female patients with histologically proven cutaneous melanoma received the investigational Low-Dose (LD) adjuvanted GSK2302025A immunotherapeutic vaccine,...” NCT01149343 ↗ |